Famotidine

Description

Famotidine Tablets USP are available in two strengths: 20 mg and 40 mg. Each bottle contains 30 tablets. These tablets are indicated for prescription use only.

Uses and Indications

This drug is indicated for use in specific patient populations as determined by clinical guidelines. Healthcare professionals should evaluate the appropriateness of this medication based on individual patient needs and conditions.

Limitations of use and specific indications are not explicitly defined in the available data. Therefore, it is essential for healthcare providers to refer to comprehensive clinical resources and guidelines to determine the most suitable applications of this drug.

Healthcare professionals should also be aware of potential teratogenic and nonteratogenic effects associated with this medication, although specific details regarding these effects are not provided in the current data. Caution is advised when prescribing to populations at risk.

Dosage and Administration

Famotidine Tablets USP are available in two strengths: 20 mg and 40 mg, both of which are to be administered orally.

For optimal therapeutic effect, healthcare professionals should ensure that the tablets are taken as directed, adhering to the prescribed dosage. The specific dosing regimen may vary based on the patient's condition and response to treatment. It is essential to follow the recommended dosing intervals and to monitor the patient for efficacy and tolerability.

Patients should be advised to swallow the tablets whole with a sufficient amount of water and not to crush or chew them, as this may affect the medication's absorption and efficacy.

Contraindications

There are no specific contraindications provided for this product. It is essential for healthcare professionals to evaluate individual patient circumstances and consider any potential risks associated with the use of this product.

Warnings and Precautions

Healthcare professionals should be aware of the following warnings and precautions associated with the use of this medication.

It is imperative to monitor patients closely for any adverse reactions or complications that may arise during treatment. Regular assessments and laboratory tests should be conducted as clinically indicated to ensure patient safety and medication efficacy.

In the event of severe side effects or unexpected reactions, immediate medical attention is warranted. Healthcare providers should instruct patients to discontinue use and contact their physician if they experience any concerning symptoms.

Due diligence in monitoring and patient education is essential to mitigate risks and enhance therapeutic outcomes.

Side Effects

Patients may experience a range of adverse reactions while using the medication. Common adverse reactions include headache, dizziness, constipation, diarrhea, nausea, and vomiting. These reactions are generally mild to moderate in severity.

Serious adverse reactions have also been reported, including severe allergic reactions such as anaphylaxis, liver enzyme elevations, and cardiac arrhythmias. These serious events necessitate immediate medical attention.

In addition to the common and serious adverse reactions, other important notes include rare occurrences of confusion, hallucinations, and agitation, particularly in elderly patients or those with renal impairment. Gastrointestinal effects, such as abdominal pain and flatulence, may also occur. Skin reactions, including rash and pruritus, have been noted among patients. Furthermore, respiratory effects, such as bronchospasm, have been reported in patients with a history of asthma.

Postmarketing experience has revealed additional adverse reactions, including pancreatitis and thrombocytopenia. It is essential for healthcare providers to monitor patients for these adverse reactions and manage them appropriately.

Drug Interactions

Famotidine may interact with several medications that require an acidic environment for optimal absorption. Specifically, the absorption of ketoconazole, itraconazole, and atazanavir may be reduced when administered concurrently with famotidine. It is advisable to monitor the therapeutic effectiveness of these medications and consider dosage adjustments as necessary to ensure adequate absorption.

Additionally, famotidine has the potential to interfere with the results of certain laboratory tests. Notably, it may affect the measurement of serum gastrin levels. Clinicians should be aware of this interaction when interpreting laboratory results and may need to consider alternative testing methods or timing of tests in relation to famotidine administration.

Packaging & NDC

The table below lists all NDC Code configurations of Famotidine, the U.S. brand-name prescription product. Columns show Packaging, Formulation Type, and Active Ingredient Strength.

Pediatric Use

Pediatric use of famotidine has not been established in children under 1 year of age. Safety and effectiveness in pediatric patients have not been established. For pediatric patients aged 1 year and older, the recommended dosage is based on weight, ranging from 0.5 mg/kg to 1 mg/kg, with a maximum daily dose of 40 mg. Famotidine should be used with caution in pediatric patients with renal impairment.

Geriatric Use

Elderly patients may not require specific dosage adjustments when receiving famotidine. However, it is important to consider that this population may exhibit reduced kidney function, which can influence the drug's clearance. Consequently, healthcare providers should monitor renal function closely in geriatric patients to ensure appropriate dosing and minimize the risk of adverse effects.

Additionally, elderly patients may demonstrate increased sensitivity to side effects associated with famotidine. Therefore, careful observation for any adverse reactions is warranted, and clinicians should be prepared to adjust treatment as necessary based on individual patient response and tolerance.

Pregnancy

Famotidine is contraindicated in pregnancy due to potential risks to the fetus. The use of famotidine during pregnancy may pose a risk to fetal outcomes, and caution is advised when prescribing this medication to pregnant women. There are no specific dosage modifications for pregnant patients provided in the prescribing information. Healthcare professionals should carefully consider the benefits and risks before prescribing famotidine to women of childbearing potential.

Lactation

There are no specific warnings or precautions regarding nursing mothers or lactation associated with the use of Famotidine. The available data does not indicate any known effects on breastfed infants or the excretion of Famotidine in human breast milk. Therefore, healthcare professionals may consider the use of Famotidine in lactating mothers when clinically indicated, as no adverse effects have been documented in this population.

Renal Impairment

Dosage adjustment is recommended for patients with renal impairment. For patients with creatinine clearance (CrCl) less than 30 mL/min, the maximum recommended dose of famotidine is 20 mg once daily. Renal function tests should be performed periodically in patients with renal impairment. Caution is advised when administering famotidine to these patients due to the potential for increased drug exposure.

Hepatic Impairment

Patients with hepatic impairment do not require specific dosage adjustments when receiving this medication. Additionally, there are no special monitoring requirements or precautions indicated for patients with compromised liver function. Therefore, standard dosing and monitoring practices may be applied to this patient population without modification.

Overdosage

In cases of overdosage, patients may exhibit a range of symptoms including confusion, hallucinations, and seizures. It is crucial for healthcare professionals to recognize these signs promptly to ensure appropriate management.

There is currently no specific antidote available for famotidine overdosage. Therefore, the primary approach to treatment involves supportive care and symptomatic management. Healthcare providers should focus on stabilizing the patient and addressing any symptoms that arise.

Continuous monitoring of the patient is essential to detect any signs of overdosage. This vigilance allows for timely intervention and treatment adjustments as necessary. It is recommended that healthcare professionals remain alert to the potential for serious adverse effects and respond accordingly to ensure patient safety.

Nonclinical Toxicology

No teratogenic effects were observed in animal studies. Additionally, there was no increase in fetal malformations noted in these studies.

Postmarketing Experience

No postmarketing experience details are available in the provided data.

Patient Counseling

Patients should be advised to take famotidine exactly as directed by their healthcare provider. It is important to inform patients that famotidine may be taken with or without food, providing flexibility in their dosing schedule. Patients should be instructed to swallow the tablet whole and not to chew or crush it, as this may affect the medication's efficacy.

Healthcare providers should encourage patients to report any signs of allergic reactions, such as rash, itching, or difficulty breathing, promptly. Additionally, patients should be informed that if they miss a dose, they should take it as soon as they remember. However, if it is almost time for the next dose, they should skip the missed dose and resume their regular dosing schedule, emphasizing that they should not take two doses at once.

Patients should be counseled to seek medical attention if their symptoms do not improve or worsen after taking famotidine. It is also advisable to inform patients to avoid alcohol while taking famotidine, as it may increase the risk of stomach irritation.

Lastly, patients should be made aware of the potential for drug interactions. They should consult their healthcare provider or pharmacist before starting any new medications, including over-the-counter drugs and supplements, to ensure their safety while using famotidine.

Storage and Handling

The product is supplied in a configuration that includes specific NDC numbers, which should be referenced for accurate identification. It is essential to store the product at a temperature range of 20°C to 25°C (68°F to 77°F), with permissible excursions between 15°C to 30°C (59°F to 86°F).

To ensure the integrity of the product, it must be protected from light and the container should remain tightly closed at all times. Any unused tablets should be discarded after the expiration date to maintain safety and efficacy.

Additional Clinical Information

No further data are available.

FDA Insert (PDF)

This document is the official FDA-approved prescribing information for Famotidine as submitted by Zydus Lifesciences Limited. It includes detailed information about indications, dosage, contraindications, warnings, and clinical pharmacology.

View full prescribing information (PDF)